

MEETING ABSTRACT

Open Access

Copper as diagnostic marker of cancers

Magdalena Muszyńska^{1*}, Wojciech Marciniak¹, Katarzyna Jaworska-Bieniek², Katarzyna Kaczmarek², Grzegorz Sukiennicki², Marcin Lener², Katarzyna Durda², Tomasz Huzarski², Tomasz Byrski², Jacek Gronwald², Oleg Oszurek², Cezary Cybulski², Tadeusz Dębniak², Antoni Morawski¹, Anna Jakubowska², Jan Lubiński^{1,2}

From Annual Conference on Hereditary Cancers 2014
Szczecin, Poland. 25-26 September 2014

The study was conducted to determine if serum copper level could be a useful marker for selection for control examinations and if serum copper level is a risk factor in developing cancer.

Copper was quantitatively measured in diluted serum samples by inductively coupled plasma mass spectrometry (ICP-MS) using mass spectrometer (Elan DRC-e, PerkinElmer) in standard mode. In our study, there were two independent groups of patients examined. In the first, retrospective model, there were patients diagnosed with prostate cancer (n = 166) and laryngeal cancer (n = 123) matched with healthy controls. This study showed that serum copper level above 1250 µg/l may be a useful marker for laryngeal examination, but is not a useful marker for prostate cancer early detection. In the second, prospective model, there were patients diagnosed with breast cancer (n = 42) matched with unaffected controls. Serum from breast cancer patients was collected 3 - 41 months before cancer diagnosis. This part of study showed that there is a tendency that breast cancer risk is about two times lower when copper serum level is in range between 1035 - 1311 µg/l. Further investigations are needed.

Authors' details

¹Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland. ²Read - Gene, S.A., Grzeczpnica, Poland.

Published: 26 November 2015

doi:10.1186/1897-4287-13-S2-A7

Cite this article as: Muszyńska et al.: Copper as diagnostic marker of cancers. *Hereditary Cancer in Clinical Practice* 2015 **13**(Suppl 2):A7.

¹Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
Full list of author information is available at the end of the article

Submit your next manuscript to BioMed Central
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

